AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article

Parthenolide suppresses colorectal adenoma progression by restraining mast cell degranulation-associated epithelial remodeling

Shunji Liua,Δ, Jiazheng Lia,Δ, Ting Lib,Δ, Qinchang Zhangc, Rui Wua, Tianyi Zhanga, Haibo Chengc, Wen Lvb( ), Yang Suna( ), Lisha Zhouc( )
State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing 210023, China
Hangzhou Medical College, Hangzhou 310053, China
Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China

∆ These authors contributed equally to this work.

Show Author Information

Abstract

Colorectal adenomas are major precursors of colorectal cancer, yet pharmacological strategies for intercepting adenoma progression remain limited. Increasing evidence suggests that immune–epithelial interactions contribute to early neoplastic remodeling; however, the role of mast cells in this process and their therapeutic relevance remain incompletely understood. This study aimed to identify potential therapeutic compounds for colorectal adenoma and to investigate the cellular and molecular mechanisms underlying their effects. Single-cell transcriptomic analysis was integrated with A Single-cell Guided Pipeline to Aid Repurposing of Drugs (ASGARD) to identify candidate compounds for colorectal adenoma. The therapeutic efficacy of parthenolide (PTL) was evaluated in ApcMin/+ mice by histopathological analyses. Single-cell RNA sequencing, epithelial subclustering, pseudotime analysis, pathway enrichment, and cell-cell communication analysis were subsequently performed to characterize PTL-associated remodeling of the adenoma microenvironment. Mast-cell activation and degranulation were further examined using cellular assays, and mast cell-epithelial interactions were investigated using conditioned medium and organoid models. ASGARD analysis prioritized PTL as a candidate compound capable of reversing adenoma-associated transcriptional alterations. PTL treatment alleviated pathological abnormalities and aberrant epithelial proliferation in ApcMin/+ mice. Single-cell analysis revealed remodeling of epithelial states during adenoma development, characterized by alterations in progenitor-like and Wnt-responsive epithelial populations, which were partially reversed following PTL treatment. Notably, adenoma progression was associated with a mast-cell transcriptional state enriched in granule-related programs. This mast-cell signature correlated with the abundance of Wnt-responsive epithelial cells, linking mast-cell activation to epithelial-state remodeling and PTL treatment attenuated these alterations. These findings identify PTL as a potential pharmacological intervention for colorectal adenoma and suggest that its therapeutic effects involve modulation of mast cell–epithelial interactions and aberrant epithelial remodeling.

References

【1】
【1】
 
 
Chinese Journal of Natural Medicines
Pages 1509-1521

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Liu S, Li J, Li T, et al. Parthenolide suppresses colorectal adenoma progression by restraining mast cell degranulation-associated epithelial remodeling. Chinese Journal of Natural Medicines, 2026, 24(12): 1509-1521. https://doi.org/10.1016/S1875-5364(26)61237-X

4

Views

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 12 August 2026
Revised: 14 September 2026
Accepted: 29 September 2026
Published: 20 December 2026
© 2026, China Pharmaceutical University.